More than 70,000 Ethereum (CRYPTO: ETH) coins have been burned or removed from the network’s circulation.
The transaction fee-burning update, EIP-1559, came into effect on August 5.
The EIP-1559 burns ETH that had been used to pay for transactions on the Ethereum network.
Before EIP-1559, the Ethereum network didn’t burn tokens; instead, gas fees went to Ethereum miners, a decentralized network of powerful computers that keep the network running.
The network is used to determine the gas price according to the demand.
EIP-1559 replaced that with a flat fee which costs 32 gwei ($2.1) to process a simple transaction in 3 minutes.
It costs approximately $8.80 to transfer a token on NFT marketplaces.
Ethereum stakers verify transactions by pledging ETH to the Ethereum 2.0 smart contract.
According to data from blockchain analytics firm Nansen, the amount staked on Ethereum surpassed 7 million ETH, worth $22.9 billion.
Staked ETH is locked until an update that will follow the “merge”—when Ethereum 1.0 and 2.0 communicate for the first time.
Also read: Ethereum Already 'Flipped' Bitcoin In This Part Of The World
Best Stocks To Watch Right Now: Infinera Corporation(INFN)
Infinera Corporation provides optical networking equipment, software, and services to communications service providers, Internet content providers, cable operators, and subsea network operators worldwide. Its products include digital transport node (DTN) platform that utilizes photonic integrated circuit technology to enable digital processing and management of data with the capability to generate wavelength division multiplexing (WDM) wavelengths and to add, drop, switch, manage, protect, and restore network traffic digitally; line systems that provide the management communications channel between network nodes and allow customers to manage capacity on network; and ATN platform that is used to extend the digital optical network architecture benefits of the DTN platform, and used as standalone WDM access systems. The company also provides IQ Network Operating System, an embedded software operating system that enables customers to simplify and speed up the tasks they perfor m to deliver, differentiate, and manage services; and a set of standards-based network and element management tools and operations support system integration interfaces to manage DTN and ATN platforms. In addition, it offers various product support services, including hardware and software technical support, installation and deployment, spares management, first line maintenance, on-site technical support, product technical training, and extended product warranties. The company?s customers include competitive carriers, multiple system operators, incumbent carriers, research and education/government organizations, and resellers. Infinera Corporation markets and sells its products and related support services primarily through its direct sales force, as well as through distribution or support partners. The company, formerly known as Zepton Networks, was founded in 2000 and is headquartered in Sunnyvale, California.
- [By ]
Get a free copy of the Zacks research report on Infinera (INFN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Timothy Green]
Shares of Infinera Corp. (NASDAQ:INFN) jumped on Monday, after the optical networking company was upgraded by an analyst for the second time in less than a month. Infinera reported solid fourth-quarter results in February, which led to the first upgrade. The stock was up about 9.7% at market close.
Best Stocks To Watch Right Now: Ligand Pharmaceuticals Incorporated(LGND)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The companys partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, blood disorders, anti-coagulant, pain, depression, allergy, sun damage, restless leg/parkinson’s, cognitive disorders, oncology, and inflammation. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis, Amgen, Inc, Merck & Co., Inc., Pfizer Inc., Celgene, Gilead, Janssen, Baxter International, Inc., and Eli Lilly and Company. The company was founded in 1987 and is headquartered in La Jolla, California.
- [By Max Byerly]
Media coverage about First Bancorp (NASDAQ:FNLC) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. First Bancorp earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the bank an impact score of 45.7895413212244 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
- [By Shane Hupp]
News headlines about First Bancorp (NASDAQ:FNLC) have been trending somewhat positive recently, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. First Bancorp earned a news impact score of 0.15 on Accern’s scale. Accern also gave media headlines about the bank an impact score of 47.3922417488866 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
- [By Shane Hupp]
First Bancorp (NASDAQ: FNLC) and Industrial & Cmrcl Bnk f China (OTCMKTS:IDCBY) are both finance companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.
- [By Shane Hupp]
Media stories about First Bancorp (NASDAQ:FNLC) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. First Bancorp earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media headlines about the bank an impact score of 45.5895151979188 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Best Stocks To Watch Right Now: ICON plc(ICLR)
ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It develops, manages, and analyzes programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company also offers clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics, and laboratory services. Its clinical development services include investigator recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety monitoring, risk-based monitoring, clinical data management, interactive response technologies, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, health economics, market access and commercialization services, strategic analysis and data operations, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, and study protocol preparation. The companys clinical development services also comprise regulatory consulting, product development planning, strategic consulting, pricing and market access consulting, strategic resourcing, electronic endpoint adjudication, sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, biomarker development, adaptive trial design and execution, medical device trials, and healthcare communication services. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.